Tirzepatide Reduces Albuminuria in Patients with T2D: Post-hoc Pooled Analysis of SURPASS 1-5

Does tirzepatide (5, 10, 15 mg) reduce urine albumin-creatinine ratio (UACR) compared to placebo or other diabetes medications? Methods : In this post-hoc analysis, UACR (% difference) for TZP (5, 10, 15 mg) vs comparators (COMPs) was analysed. Analyses were conducted in the pooled entire SURPASS 1-5 population and populations pooled by COMP: placebo (SURPASS 1 & 5); active (SURPASS 2 [semaglutide 1 mg] & SURPASS 3-4 [insulins]); and insulins. In each pooled population, data were examined in all patients and in subgroups defined by baseline UACR ≥30 mg/g or eGFR<60 mL/min/1.73m^2. Mixed model for repeated measures was used to analyse on-treatment data from baseline up to the end of treatment visit. Results : UACR data was available in 6263 patients of whom 1846 had UACR ≥30 mg/g and 537 had eGFR<60 mL/min/1.73m^2. UACR decreased more with TZP 5, 10, and 15 mg vs COMPs in pooled SURPASS 1-5 and consistently across pooled placebo, active, and insulin COMP studies. UACR lowering appeared more pronounced in subgroups with baseline UACR ≥30 mg/g or eGFR<60 mL/min/1.73m^2. Conclusion : In people with T2D, including those with reduced kidney function, TZP decreased UACR vs COMPs to a clinically relevant degree, supporting a potential kidney protective effect. ^ denotes square root of in this submission Publication History Article published online: 18 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany